Literature DB >> 1456851

How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value.

R H Shmerling1, T L Delbanco.   

Abstract

BACKGROUND: The rheumatoid factor (RF) is frequently ordered in an effort to detect disease, yet its diagnostic utility has not been thoroughly examined. To determine the test's sensitivity, specificity, positive predictive value, and negative predictive value, we analyzed tests ordered in our institution.
METHODS: We performed a retrospective analysis of all 86 patients with a positive RF over a 6-month period identified consecutively soon after the test was ordered. A similar analysis was applied to 86 seronegative patients selected at random from a total seronegative population of 477 during the same period. The patients represented the primary care and subspecialty practices and inpatient wards of a 504-bed university teaching hospital.
RESULTS: A positive RF result was strongly associated with rheumatoid arthritis or another rheumatic disease. For rheumatoid arthritis, sensitivity = 0.28 and specificity = 0.87, while for any rheumatic disease, sensitivity = 0.29 and specificity = 0.88. The positive predictive values for rheumatoid arthritis and any rheumatic disease were 0.24 and 0.34, respectively, and the negative predictive values were 0.89 and 0.85, respectively. Seropositive patients were slightly older (55 vs 49 years old), but the incidence of false-positive RFs among the elderly (69%) was not significantly higher than among younger patients (65%). The cost per true-positive RF result was $563.
CONCLUSIONS: In this study, most positive RF results were not helpful since the majority represented false-positive results. The low positive predictive value of the RF casts doubt on the utility of the RF in the diagnostic evaluation of patients. Contrary to traditional clinical expectations, the diagnostic utility of the RF may be greatest when it is negative. However, the subset of patients with seronegative rheumatic disease reduces the test's power to exclude such disorders even when the RF is negative. Given the test's limitations, clinicians should reconsider their expectations when ordering an RF. The utility of the RF may improve if it is ordered more selectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1456851

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  13 in total

Review 1.  Mechanisms and models of immune tolerance breakdown in the ovary.

Authors:  Mickie H Cheng; Lawrence M Nelson
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

Review 2.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

3.  Juvenile idiopathic arthritis among Nigerians: a case study.

Authors:  Olufemi O Adelowo; A Umar
Journal:  Clin Rheumatol       Date:  2010-03-01       Impact factor: 2.980

4.  Decoding laboratory test names: a major challenge to appropriate patient care.

Authors:  Elissa Passiment; James L Meisel; John Fontanesi; George Fritsma; Samir Aleryani; Marisa Marques
Journal:  J Gen Intern Med       Date:  2012-11-29       Impact factor: 5.128

5.  Predictive value of anti-citrullinated peptide antibodies: a real life experience.

Authors:  Abdulla Watad; Nancy Agmon-Levin; Boris Gilburd; Merav Lidar; Howard Amital; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

6.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

7.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

Authors:  A Kastbom; G Strandberg; A Lindroos; T Skogh
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

8.  The use of rheumatoid factors in clinical practice.

Authors:  M J Thomas; A Adebajo; H M Chapel; M Webley
Journal:  Postgrad Med J       Date:  1995-11       Impact factor: 2.401

9.  Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis.

Authors:  Susan Tseng; A Hari Reddi; Paul E Di Cesare
Journal:  Biomark Insights       Date:  2009-02-17

10.  Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.

Authors:  Pascale Nicaise Roland; Sabine Grootenboer Mignot; Alessandra Bruns; Margarita Hurtado; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Olivier Meyer; Sylvie Chollet Martin
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.